Insulin Degludec in Critically Ill Patients With Type 2 Diabetes Mellitus: A Prospective Interventional Study
Authors' conclusion
In critically ill patients with type 2 DM, one-fourth of BG levels were within the glycemic target (140-180 mg/dL) with insulin degludec plus insulin regular correctional doses. The median BG levels were in target starting the second day of insulin degludec therapy. The favorable BG variability using insulin degludec merits further investigation for effect on clinical outcomes.
Study context
- Population
- Critically ill patients with T2D
- Participants
- 155 patients
- Outcome
- Percentage of BG levels within target of 140 to 180 mg/dL
Methodological detailssingle-group, blood glucose (BG) levels assessed every 6 hours
- Single-group
- BG levels assessed every 6 hours
Main finding
As reported in the abstract
BG levels within target 140–180 mg/dL
Percentage of BG levels within the target
28.5%
Observational data: associations, not effects.
Secondary outcomes
Median BG levels
- First day median BG within target; remained within target for 1 week
- day 2
BG variability (coefficient of variation)
- BG variability, coefficient of variation
- 26%
Safety
| Outcome | Values |
|---|---|
| Severe hypoglycemia | Insulin degludec 3.2% |
Original publication
Insulin Degludec in Critically Ill Patients With Type 2 Diabetes Mellitus: A Prospective Interventional Study. Endocr Pract. Published 25 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →